IRVINE, CA., September 1, 2023 / OrthoSpineNews / – HippoFi, Inc. (OTCPK: ORHB) – HippoFi, in affiliation with its wholly owned subsidiary PUR Biologics, is getting ready to unveil the main points of the closing of its strategic partnership and asset acquisition with a prime 5 international chief within the orthopedic trade. This partnership requires a collaboration of distinct experience and expertise, aiming to form the long run panorama of spinal biologics.
“We look ahead to sharing extra particulars in subsequent week’s formal announcement, it is a pivotal second for our firm,” shared CJ Wiggins, Govt Chairman and CEO of HippoFi.
HippoFi’s constant management in spinal biologic developments and observe document of success positions this announcement as a key trade improvement.
About HippoFi, Inc.
HippoFi, Inc. (OTCPK: ORHB) delivers its cutting-edge healthcare improvements and propriety applied sciences by an intensive gross sales channel community, whereas implementing first-to-market options within the multibillion-dollar biotech, fintech, and synthetic intelligence (AI) markets. HippoFi includes three segments: Regenerative Therapeutics, Digital Funds, and AI, and make the most of the identical buyer channels to commercialize options, drive income, and enhance affected person outcomes. HippoFi, Inc. is publicly traded beneath the image: ORHB and is headquartered in Irvine, California, USA.
About PUR Biologics
PUR Biologics, a completely owned subsidiary of HippoFi, Inc. (OTCPK: ORHB), is a number one biologic firm dedicated to supporting surgeons and hospitals in offering the perfect care for his or her sufferers. PUR Biologics’ full line of biologic merchandise at present consists of superior allografts and demineralized extracellular matrices (d-ECM), modern artificial bone-forming options, cellular-derived tissues, and a way forward for patented and next-generation regenerative stem cell and progress factor-driven therapeutics for treating osteoarthritis and cartilage regeneration.
For extra info, please go to: www.HippoFi.com and www.PURbiologics.com
Contact:
Jason Brown
Shareholder Communications
HippoFi, Inc.
612-209-7565
Discussion about this post